Stock Review for Biotech's Investors -- Bioverativ, ACADIA Pharma, Inovio Pharma, and Biogen
NEW YORK, Dec. 15, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on BIVV, ACAD, INO, and BIIB which is a click away at www.wallstequities.com/registration. On Thursday, December 14, 2017, the NASDAQ Composite ended the trading session at 6,856.53, down 0.28%; the Dow Jones Industrial Average edged 0.31% lower, to finish at 24,508.66; and the S&P 500 closed at 2,652.01, slightly dropping 0.41%. Losses were broad based as all sectors ended the day in negative. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Bioverativ Inc. (NASDAQ: BIVV), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Biogen Inc. (NASDAQ: BIIB). Sign up today for free and learn why our members refer to our research coverage as the 'best out there':
www.wallstequities.com/registration
Bioverativ
Waltham, Massachusetts headquartered Bioverativ Inc.'s stock finished Thursday's session flat at $53.47 with a total trading volume of 1.37 million shares, which was above its three months average volume of 1.22 million shares. The Company's shares have advanced 12.57% since the start of this year. The stock is trading below its 50-day moving average by 2.40%. Additionally, shares of Bioverativ, which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the US and Japan, have a Relative Strength Index (RSI) of 53.55. Signing up now gives you access to the free research coverage on BIVV at: www.wallstequities.com/registration/?symbol=BIVV
ACADIA Pharmaceuticals
On Thursday, shares in San Diego, California headquartered ACADIA Pharmaceuticals Inc. recorded a trading volume of 1.12 million shares. The stock ended the session 3.24% lower at $28.97. The Company's shares have advanced 16.16% over the last twelve months. The stock is trading below its 50-day moving average by 10.26%. Moreover, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have an RSI of 42.75. Get access to our top-rated research, including the free report on ACAD at: www.wallstequities.com/registration/?symbol=ACAD
Inovio Pharmaceuticals
Plymouth Meeting, Pennsylvania headquartered Inovio Pharmaceuticals Inc.'s shares closed the day 4.04% lower at $4.28. The stock recorded a trading volume of 1.33 million shares, which was above its three months average volume of 1.20 million. The stock is trading below its 50-day moving average by 19.33%. Additionally, shares of Inovio Pharma, which develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases, have an RSI of 35.97. Click here to subscribe for a free membership which welcomes you with our report on INO at: www.wallstequities.com/registration/?symbol=INO
Biogen
Shares in Cambridge, Massachusetts headquartered Biogen Inc. finished 2.17% lower at $323.55. The stock recorded a trading volume of 1.17 million shares. The Company's shares have advanced 22.71% over the last twelve months and 23.87% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.99% and 11.19%, respectively. Furthermore, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide, have an RSI of 51.02. Join our big investor community at Wall St. Equities today and start so with your free report on BIIB at: www.wallstequities.com/registration/?symbol=BIIB
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----bioverativ-acadia-pharma-inovio-pharma-and-biogen-300571937.html
SOURCE Wall St. Equities
